


# Antibody Engineering & Therapeutics

December 9-13, 2018  
Manchester Grand Hyatt  
San Diego, CA



The Most Innovative Science Presented by Leading Industry and Academic Experts  
The Largest Exhibition Devoted to Antibody Engineering  
The Leading Forum to Partner with Global Antibody Innovators and Suppliers



## Keynote Speakers Share Strategies to Accelerate Your Antibody Molecules



**TCR SEQUENCING: TRANSFORMING THE DIAGNOSIS AND CARE OF CUTANEOUS T CELL LYMPHOMAS**

**Rachael A. Clark, M.D., Ph.D.**

Shing-Yiu Yip and Cecilia M. Hepp Associate Professor of Dermatology, HARVARD MEDICAL SCHOOL



**BIOINFORMATICS AND COMPUTATIONAL APPROACHES TO PROTEIN ENGINEERING**

**David Baker, Ph.D.**

Professor of Biochemistry, UNIVERSITY OF WASHINGTON



**BENRALIZUMAB, A MONOCLONAL ANTIBODY ENGINEERED FOR ENHANCED NK-CELL MEDIATED EOSINOPHIL DEPLETION**

**Bahija Jallal, Ph.D.**

President, MedImmune and Executive Vice President, ASTRAZENECA



**EXPLOITING THE DIVERSE FUNCTIONS OF FcRn TO GENERATE THERAPEUTICS**

**Sally Ward, Ph.D.**

Professor, Department of Molecular and Cellular Medicine, TEXAS A&M UNIVERSITY HEALTH SCIENCE Center and Centre for Cancer Immunology, UNIVERSITY OF SOUTHAMPTON

Register by June 29 and Save \$500 [www.antibodyeng.com](http://www.antibodyeng.com)

**KNect365**  
Life Sciences



**900+**

## ANTIBODY SCIENTISTS AND EXECUTIVES

Fast-track your antibody research to the clinic and beyond by collaborating with leading pharma, biotech, academia and solution providers from North America, Asia and Europe.



**135+**

## GLOBAL SPEAKER PRESENTATIONS

Expand your pipeline of antibody therapeutics by hearing case studies, new data and industry updates from experts working across the entire spectrum of antibody discovery and development.



**125+**

## POSTERS

Stay at the forefront of antibody innovation by accessing cutting-edge and unpublished data from fellow attendees.



**75+**

## EXHIBITORS

Accelerate your promising therapeutic towards commercial success by connecting with leading technology and service providers.



## PRE-CONFERENCE TRAINING COURSE

Sunday, December 9, 2018, 9:00am-5:00pm

### Introduction to Antibody Engineering

Instructor: David Bramhill, Ph.D., Bramhill Consulting, LLC and Research, Corporation Technologies

\*Additional registration fee applies. See the pricing grid in this brochure or visit the website for more details

## PRE-CONFERENCE WORKSHOPS

Sunday, December 9, 2018, 1:00pm-5:00pm

### Workshop A: Next-generation Sequencing for Antibody Library Analysis and Monoclonal Discovery and Engineering

Workshop Moderators:

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland

### Workshop B: Immuno-Engineering 101: An Introduction to the Immune System

Workshop Moderators:

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom

James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

\*Additional registration fee applies. See the pricing grid in this brochure or visit the website for more details

## MAIN CONFERENCE

Monday-Thursday, December 10-13, 2018

### Novel Indications for Therapeutic Antibodies

Session Chair: James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

#### Targeting Eosinophils and Mast Cells with AK002: A Novel Treatment Approach

Christopher Bebbington, Ph.D., Chief Scientific Officer, Allakos, Inc.

#### Collagen Fibrillogenesis Inhibitory Antibody

Andrzej Fertala, Researcher, Thomas Jefferson University

#### GDF-15 Receptor

David Shen, Ph.D., SVP, Head of Biologics Research and CMC, NGM Biopharma

#### IL1RAP as a Therapeutic Target

Göran Forsberg, Ph.D., Chief Executive Officer, Cantargia AB, Sweden

#### LRP6 and Fibrosis

Andrew Mendelsohn, Scientist, Wntgen LLC

### Antibody Developability

Session Chair: K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

#### In vitro Measures to Predict PK

Laura Lin, Ph.D., Director of Biophysics and Analytics, Global BioTherapeutic Technologies, Pfizer, Inc.

#### Antibody Colloidal Stability

Peter Tessier, Ph.D., Albert M. Mattocks Professor of Pharmaceutical Science, Chemical and Biological Engineering, University of Michigan

#### Biochemical Developability of the Clinical Antibody Landscape

Yingda Xu, Ph.D., Director, Protein Analytics, Adimab

#### Extensional Flow Induced mAb Aggregation

David Brockwell, Ph.D., Associate Professor, School of Molecular and Cellular Biology, University of Leeds, United Kingdom

#### Improving Biotherapeutic Development Through Structured Data Utilization

Randal Ketchum, Ph.D., Vice President of Molecular Design, Just Biotherapeutics

#### Host Cell Proteins in mAb Manufacturing

Kelvin Lee, Ph.D., Gore Professor of Chemical & Biomolecular Engineering, University of Delaware

### Libraries, Display, Selection and Screening

Session Chair: Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

#### Bispecific Target Discovery by High Throughput Functional Screening of Hundreds of Combinations of Different Target Pairs

Helene Finney, Ph.D., Director, Functional Screening, UCB, United Kingdom

#### Novel Techniques for Fab Library Generation and Antibody Hit Discovery Using Yeast Surface Display

Stefan Zielonka, Ph.D., Principal Scientist, Protein Engineering & Antibody Technologies, Merck KGaA/EMD Serono, Germany

#### Synthetic Antibody Repertoire Design and Generation in Mammalian Cells Using CRISPR-Cas9-mediated homology-directed Mutagenesis

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland

#### High Throughput Platform for Batch Reformatting of scFvs to IgGs for Functional Screening

Ben Kemp, Scientist, Medimmune (Invited)

#### Interpreting Antibody Function on a Repertoire Scale

Brandon Dekosky, Ph.D., Assistant Professor, Pharmaceutical Chemistry and Chemical Engineering, The University of Kansas

## Microbiome

### Session Co-Chairs:

Bertrand Routy, M.D., Ph.D., Principal Scientist, CRCHUM and Assistant Professor of Hematology-Oncology, Department of Medicine, University of Montreal, *Canada*

Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and Sparring Biologics B.V., *The Netherlands*

### Microbiome Therapeutics

Lorenzo Tibaldi, Ph.D., Project Leader - Drug Discovery, Enterome Bioscience, *France*

### Microbiome & Checkpoint Therapy

Bertrand Routy, M.D., Ph.D., Assistant Professor Hemato-oncology CHUM, University of Montreal Hospital Center, *Canada*

## Immunogenicity

### Session Co-Chairs:

Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech

Valerie Quarumby, Ph.D., Staff Scientist and Director, BioAnalytical Sciences, Genentech

### Immunogenicity in Biotherapeutic Development

Valerie Quarumby, Ph.D., Staff Scientist and Director, BioAnalytical Sciences, Genentech

### Approaches to Immune Response Mitigation - Use of Systemic and Targeted Approaches to Immune Suppression

Amy Rosenberg, Division Director, US FDA (*Invited*)

### Emicizumab Case Study: A Risk Mitigation Practice of Immunogenicity and Its Clinical Relevance

Shuichi Chiba, Ph.D., Department Manager, Safety Assessment, Chugai Pharmaceutical Co. Ltd., *Japan*

### Secukinumab Demonstrates Significantly Lower in vitro Immunogenicity Potential Compared to Ixekizumab and Other Therapeutic Antibodies

Frank Kolbinger, Ph.D., Executive Director, Novartis Pharma AG, *Switzerland*

### Vatreptacog Case Study: Retrospective Use of in silico Analysis, T cell Assays and MAPPs to Troubleshoot Unwanted Immunogenicity

Kasper Lamberth, Ph.D., Principal Scientist, Screening & Bioassay Technology, Novo Nordisk A/S, *Denmark*

## Mechanisms of Immune Attack: Clinical Stories

### Session Co-chairs:

Louis M. Weiner, M.D., Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Gregory Adams, Ph.D., Chief Scientific Officer, Eleven Biotherapeutics

### Anti-cd47 Antibody in Clinical Trials

Chris Takimoto, M.D., Ph.D., Chief Medical Officer, Forty Seven, Inc. (*Invited*)

## Vaccines and Antibodies in Infectious Disease

### Session Co-chairs:

Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute

Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and Sparring Biologics B.V., *The Netherlands*

### Imaging Complement by Phase-plate Cryo-electron Tomography from Initiation to Pore Formation

Thom Sharp, Ph.D., Assistant Professor, Leiden University Medical Center, *The Netherlands*

### Novel Antibodies Targeting Malaria

Robert Sauerwein, M.D., Ph.D., Professor, Faculty of Medical Sciences, Radboud UMC, *The Netherlands*

## CAR-T/T-cell Recruitment in Solid Tumors

### Session Co-Chairs:

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, *United Kingdom*

Janine Schuurman, Ph.D., Vice President, Research, Genmab, *The Netherlands*

### GD2-targeted CAR T Cells in Gliomas

Robbie Majzner, M.D., Instructor, Pediatrics - Hematology & Oncology, Stanford

### Oncolytic Vaccines Encoding T cell Engagers: Tumor-targeted Delivery and Anti-tumor Synergy

Christine E. Engeland, M.D., Ph.D., Physician-Scientist, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), *Germany*

### Selecting and Expanding a Patient's Own Autologous T cells Based on Cancer Cell Targets for Treatment (ACTolog)

Harpreet Singh, Ph.D., Managing Director, CSO and Co-Founder, Immatics Biotechnologies GmbH, *Germany*

### Glypicans as CAR T-Cell Therapy Targets in Cancer

Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI

### CAR-T in the Tumor Microenvironment

Senior Scientist TBA, Autolus, *United Kingdom*

## Meeting Challenges for Antibody Therapies in the Tumor Microenvironment

### Session Co-Chairs:

Janine Schuurman, Ph.D., Vice President, Research, Genmab, *The Netherlands*

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, *United Kingdom*

### Preclinical Validation of a Site-specifically Conjugated, ROR1-specific Anthracycline-ADC with Potent Immune-stimulatory Functions

Roger R. Beerli, Ph.D., Chief Scientific Officer, NBE-Therapeutics AG, *Switzerland*

### Immunotherapy with CD3 Bispecific Antibody in Immuno Competent Mouse Models

Thorbald van Hall, Ph.D., Associate Professor, Leiden University Medical Center, *The Netherlands*

### Data and Learnings from JTX-2011 and Other Earlier Stage Projects

Emma Lees, Ph.D., Senior Vice President, Research, Jounce Therapeutics

## Clonal Expansions of Lymphocytes in Immune Repertoires

*Session Co-chairs:*

Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, *Canada*

Nina Luning Prak, M.D., Ph.D., Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania

## Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases

*Session Co-chairs:*

Anne Messer, Ph.D., Professor of Biomedical Sciences, University at Albany and Principal Investigator, Neural Stem Cell Institute, Regenerative Research Foundation

Cynthia A. Lemere, Ph.D., Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School

James S. Huston, Ph.D., Chairman, The Antibody Society; Managing Member, Huston BioConsulting, LLC

## Structural and Functional Analyses of 3 Anti-pyroglutamate-3 Abeta Antibodies as the Basis for Alzheimer's Immunotherapy

Stephan Schilling, Ph.D., Scientist, Probiodrug

## Antibody Transport Vehicle (ATV): A Novel Brain Delivery Platform

Mark Dennis, Ph.D., Fellow, Denali Therapeutics

## Preclinical/Clinical Studies and Combination Therapy

*Session Chair:* Gregory Adams, Ph.D., Chief Scientific Officer, Sesen Bio

### Preclinical Studies of Targeted Radionuclide Therapy and Radiosensitization Strategies for Cancer Therapy

Marika Nestor, Ph.D., Associate Professor and Head of Research Group, Immunology, Genetics and Pathology, Uppsala University, *Sweden*

### Phase 3 Trial Results of an Anti-CD22 Immunotoxin for Hairy Cell Leukemia

Ira Pastan, Director, National Cancer Institute (*Invited*)

### Preclinical Development of an Agonistic Antibody Targeting the OX001R/OX001L Immune Escape Mechanism

Haining Huang, Ph.D., Senior Director, Immuno Oncology, Oxford BioTherapeutics, *United Kingdom*

### Cancer Therapy Revisited

H. Kaspar Binz, Ph.D., Vice President and Co-Founder, Molecular Partners AG, *Switzerland*

### Preliminary Results of the Vicinium Phase 3 VISTA Study in Subjects with High Grade Non-Muscle Invasive Bladder Cancer

Gregory Adams, Ph.D., Chief Scientific Officer, Sesen Bio

## Novel Methods to Interrogate Receptors as Targets

*Session Chair:* Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, *Switzerland*

### Developments in CyTOF and Follow-up Strategies (e.g. Linking to Oligo Barcodes)

Garry P. Nolan, Ph.D., Rachford and Carlota A. Harris Professor, Department of Microbiology and Immunology, Stanford School of Medicine

### Presentation Title TBA

Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, *Switzerland*

### Emerging Approaches and Challenges in Targeting Protein-Protein Interactions

Rami Hannoush, Ph.D., Principal Scientist & Group Leader, Genentech

### Decoding Ligand Receptor Interactions

Bernd Wollscheid, Head of Proteomics Platform, ETH Zurich, *Switzerland*

## Additional Confirmed Speakers

### Finding the Needle in the Haystack: Combining Next Generation Sequencing (NGS) and Immunoinformatics to Characterize and Screen Antibody Libraries

Khalil Mazouari, Ph.D., Immunoinformatics Consultant, AbnomX, *Belgium*

### Paired Antibody Repertoire Sequencing and Screening by Surface Display

David Johnson, Ph.D., Founder and CEO, GigaGen

### Antibody Discovery and Engineering by Analyzing Repertoire Sequence Space

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, *Switzerland*

### Clonify: Unseeded Antibody Lineage Assignment from Next-generation Sequencing Data

Bryan Briney, Ph.D., Assistant Professor, Immunology and Microbiology, The Scripps Research Institute

## Scientific Briefings

### Build Better Antibodies with Machine Learning and SynBio

Claes Gustafsson, Ph.D., Co-founder and Chief Commercial Officer, ATUM

### An Integrated Approach To Managing Immunogenicity Risk And Optimum Protein Design

Emilee Knowlton, Ph.D., Immunology Sales Specialist, ProImmune, Inc.

### Advances in Automated Microfluidic Capillary Electrophoresis for IgG Analysis, from Screening through QC, using PerkinElmer's IntelliChip™ Assays

James White, Ph.D., Senior Application Scientist, PerkinElmer

### Computational Approaches for Optimizing the Developability of Biotherapeutics

Nels Thorsteinson, Scientific Services Manager, Biologics, Chemical Computing Group, *Canada*

### A Computational Framework for Predicting Protein Liabilities & Improvement of Antibody Developability

Johannes Maier, Ph.D., Principal Scientist, Schrodinger

### Speeding Discovery and Development with High-Throughput, High-Precision Characterization of Clonal Populations

Troy Lionberger, Ph.D., Senior Manager, Technology Development, Berkeley Lights

# RESERVE YOUR EXHIBIT BOOTH OR SPONSORSHIP TODAY!

KNect365's Antibody Engineering and Antibody Therapeutics conference offers a unique opportunity to reach the pre-eminent researchers working in this important field of science from both the industry and academic sectors.

The 28th Antibody Engineering & Therapeutics conference (the longest running such event in the world) is dedicated to current developments in the basic science of this important field, and also tracks the clinical progress of antibody based drug products.

## A Format Designed for Your Interactions with Conference Audience

- Two evening cocktail receptions in an exhibit/poster hall with more than 100 scientific posters
- Two luncheons in exhibit/poster hall
- Exhibit/poster hall networking time open during sessions
- Corporate suites for private meetings

### Platinum Sponsor

Ligand®

### Gold Sponsor

 carterra®

### Silver Sponsors

 aldevron

 ATUM

### Session Sponsors

 ABZENA  
Enabling better biopharmaceuticals

 aldevron

 ATUM

 BERKELEY LIGHTS

 carterra®

 CHEMICAL COMPUTING GROUP

 fusion antibodies  
from genes to proteins to antibodies

 geneious biologics

 HARBOUR BIOMED

 isogenica

Ligand®

 MabPlex

 MaxCyte®

 PALL FortéBio

 PerkinElmer®  
For the Better

 PROIMMUNE  
www.proimmune.com

SCHRÖDINGER

 SGDNA  
A Synthetic Genomics, Inc. Company

### Registration Sponsor

Ligand®

### Lanyard Sponsor

 MabPlex

### Notepad & Pen Sponsor

 OmniAb

## Exhibitors

(as of June 5, 2018)

Abveris Antibody  
Abzena  
Acrobiosystems  
Aldevron  
Antibody Solutions  
Aragen Bioscience  
Atum  
AvantGen  
Avid Bioservices  
Benchling  
Berkeley Lights, Inc.  
Bionova Scientific  
BPS Bioscience  
Carterra  
Chemical Computing Group  
Chempartner  
Fusion Antibodies  
Geneious Biologics  
Genovis Inc.  
Gyros Protein Technologies  
Harbour BioMed  
Icosagen Cell Factory  
ImmunoPrecise Antibodies  
IntelliCyt  
KBI BioPharma  
LakePharma  
MabPlex  
Maxcyte  
ModiQuest Research  
NanoCollect Biomedical  
Novoprotein  
Pall ForteBio  
PerkinElmer  
PhyNexus  
Promega  
ProZyme  
Roche Custom Biotech  
Sapidyne Instruments  
Schrödinger  
Sphere Fluidics Limited  
Thermo Fisher Scientific  
Thomson Instrument  
TTP Labtech  
Twist Bioscience

Exhibit and sponsorships are limited! To build your custom sponsorship package, contact:

(A-L) Aimee Croke, [Aimee.Croke@KNect365.com](mailto:Aimee.Croke@KNect365.com), +1.857.504.6697

(M-Z) Kristin Skahan, [Kristin.Skahan@KNect365.com](mailto:Kristin.Skahan@KNect365.com), +1.857.504.6730




<b>Main Conference</b> (Tues-Fri)	Register by June 29, 2018 <b>SAVE \$500</b>	Standard Rate	<b>INDUSTRY ADD-ON OPTIONS</b> Half Day Workshop (Monday PM): <b>\$499</b> Full Day Training Course (Mon): <b>\$899</b> Poster Presentation: <b>\$125</b>
<b>INDUSTRY RATES</b>	<b>\$2,199</b>	\$2,699	
<b>INDUSTRY GROUP RATES</b>	<b>\$1,999 per person</b>	\$2,499 per person	
<b>Main Conference</b> (Tues-Fri)	Register by June 29, 2018 <b>SAVE \$350</b>	Standard Rate	<b>ACADEMIC/GOVT ADD-ON OPTIONS</b> Half Day Workshop (Monday PM): <b>\$299</b> Full Day Training Course (Mon): <b>\$599</b> Poster Presentation: <b>\$0</b>
<b>ACADEMIC/GOVT* RATES</b>	<b>\$749</b>	\$1,099	
<b>ACADEMIC/GOVT* GROUP RATES</b>	<b>\$649 per person</b>	\$999 per person	

\*Academic/Government rates are extended to full-time employees of government, universities and university-affiliated hospitals only. To register for only a training course or symposia, please contact Leslie Wu at E-mail: [lwu@knect365.com](mailto:lwu@knect365.com); Tel: +1 646-895-7434.

## REGISTER A GROUP OF 4+ AND SAVE UP TO \$200/PERSON

Companies that register 4+ attendees are eligible to receive up to an additional \$200 savings per person off the current registration rate. Register your group today at the lowest rate by contacting Leslie Wu at E-mail: [lwu@knect365.com](mailto:lwu@knect365.com); Tel: +1 646-895-7434



### Present a Poster to Showcase Your Company's Latest Research

Highlight your company's exciting research by presenting a scientific poster, which will be displayed in the exhibit & poster hall during the event. You must be a registered attendee to present a poster. Poster fee is \$125 for industry attendees and free for academic/government attendees. The deadline to submit your poster is November 7, 2018.



### Sponsorship/Exhibition Opportunities

Highlight your expertise directly to 800+ scientists and high level decision makers and influencers working across antibody engineering, antibody therapeutics and protein discovery and development by becoming an event sponsor or exhibitor. Contact Aimee Croke at [aimee.croke@knect365.com](mailto:aimee.croke@knect365.com) or (857) 504-6697 for pricing and package details, or to see a sample attendee list from Antibody Engineering 2017. Reserve your spot early to ensure company placement in our printed brochure.



#### Venue Information:

### Manchester Grand Hyatt San Diego

1 Market Place, San Diego, CA 92101

Phone: (888) 421-1442

#### Special Attendee Room Rate: \$235/night + tax

Please call the hotel directly at the number above or book online and reference "Antibody Engineering" to receive the reduced room rate. Special hotel rates are good through November 16, 2018 or until room block is sold-out.